Search

Background Isoniazid (INH) is well known as a first-line anti-tuberculosis, while some studies demonstrate that it has anti-inflammatory activity via a different mechanism such as inhibition the production of IL-1, ROS, activation of PPARγ expression, inhibition of the transcriptional regulatory activity of NF-κB and AP-1. The aim of this study, investigate the anti-inflammatory effect of INH and INH combined with Sulfasalazine-loaded nanoparticles (NPs) in the ulcerative colitis mouse model. Methods To investigate the anti-inflammatory effect of INH and NPs in the ulcerative colitis mice model, we evaluated the effect of INH clinical symptoms and colonic mucosal histology in colitis. Result The present study demonstrates that combination therapy of INH with sulfasalazine as well as NPs reduces the symptom of ulcerative colitis and improved disease activity index include body lose weight, diarrhea, rectal bleeding, colonic length, spleen weight, and colon histopathological score in DSS-induced colitis mice model. Conclusion Our results suggest that the nanoforms of INH with sulfasalazine enhances the therapeutic effect of the drugs in the treatment of ulcerative colitis.

Ibuprofen is a widely prescribed non-steroidal and anti-inflammatory drug, which is practically insoluble in water and causes gastrointestinal (GI) side effects. Ibuprofen-phosphathidylcholine association (IPA) was prepared by refluxing ibuprofen and phosphathidylcholine in three different molar ratios (1:0.25, 1:0.5 and 1:1) in aim to induce the amorphous nature of ibuprofen and increase its solubility. The characteristics of IPA were evaluated by H1-NMR, FT-IR spectra, X ray diffraction (XRD), differential scanning calorimetry (DSC), drug content, photon correlation spectroscopy, computational molecular simulation, solubility and in vitro dissolution study. Computational molecular simulation, DSC, FT-IR, H1-NMR and XRD patterns confirmed the reaction between carboxyl group of ibuprofen and polar moiety of phosphathidylcholine. IPAs showed an increase in solubility in phosphate buffer medium (pH 7.2) and a decrease in solubility in HCl medium (pH 1.2). The IPA dissolution rate increased in the simulated intestinal medium, whereas the dissolution rate of the IPA decreased in the simulated gastric medium. It is concluded that the phosphatidylcholine association of ibuprofen may be of potential use for improving the ibuprofen solubility and hence its bioavailability. Furthermore, considering decrease of dissolution rate of IPA in acidic medium, it may also reduce GI toxicity of ibuprofen. Moreover, comparing different molar ratios of IPA, there is no significant difference in their characteristics and dissolution profiles.

In the current study, in order to augment the therapeutic efficacy of curcumin, thermo-sensitive biodegradable hydrogel composed of poly (e-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly (e-caprolactone-co-lactide) (PCLA-PEG-PCLA) incorporating curcumin-loaded polyethylene glycol-b-polylactide (mPEG-PLA) nanopolymersome was prepared. The final objective of this study was to introduce a biodegradable thermo-responsive, injectable hydrogel that can prolong and localize therapeutic effects of curcumin. The obtained results demonstrated that the encapsulation of curcumin nanopolymersome in the thermos-sensitive hydrogel provided the sustained controlled release of the encapsulated curcumin. The rheological investigation demonstrated that the viscosity of the prepared composite hydrogel (20% copolymer solution) was low which made it intratumorally injectable. However, at physiological temperature (37 °C), system was in gel state with good mechanical strength thereby providing sustained release of the encapsulated platform upon intratumoral administration. In vivo administration of the prepared composite hydrogel incorporating curcumin nanopolymersome to ectopic C6 glioma tumor model in nude mice illustrated ideal therapeutic response of the prepared composite platform. The key innovation of the current study was the development of biodegradable, injectable therapeutic-loaded implant to improve the outcomes of glioma treatment while reducing the treatment complications.